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Non-Hodgkin Lymphoma
Introduction
Survival following childhood B-cell non-Hodgkin lymphoma
(B-NHL) [i.e. Burkitt lymphoma (BL) and diffuse large B-cell
lymphoma (DLBCL)] or mature B-cell leukemia (B-AL) has
increased dramatically from a rate of approximately 35% to
90% during recent decades, particularly in France with the
Lymphomes Malins B (LMB) protocols of the Société Française
d’Oncologie Pédiatrique (SFOP)/Société Française des Cancers de
l’Enfant (SFCE). These protocols include dose escalation of anti-
neoplastic agents, such as cyclophosphamide, high-dose (HD)
methotrexate and cytarabine.1–6
The few published studies on the prognosis of relapsed B-
NHL/B-AL in children7–11 show poor outcomes after intensive
initial treatment. However, certain studies have reported that
treatment with HD chemotherapy with autologous
hematopoietic stem cell transplantation (HSCT) cured some
patients with relapsed B-NHL/B-AL.8–10,12–16 The role of adjuvant
CD20 monoclonal antibodies remains to be defined.11,17–19
In this study, we retrospectively reviewed relapses in
patients enrolled in one of the three recent LMB studies. Cases
of primary refractory B-NHL/B-AL were not considered. The
aim was to describe the relapses, to analyze the results of the
therapeutic strategy, and to identify prognostic factors for sur-
vival after relapse.  
Methods
Patients
We retrospectively reviewed relapsed B-NHL/B-AL in French,
Belgian, and Dutch patients prospectively enrolled in the SFOP/SFCE
LMB89,2 French-American-British (FAB)/LMB96,3,5,6 and LMB2001
studies between July 1989 and March 2007. From the FAB/LMB96
study, only SFOP patients were included in the current study. The
studies were approved by the SFOP scientific committee or/and
National Ethics Committee. Parents/legal guardians provided
informed consent for inclusion of their children in the studies in accor-
dance with the Helsinki Declaration. Relapse was defined as any
tumor progression after achieving complete remission. 
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To describe relapsed B-cell lymphoma or leukemia in children/adolescents treated with a “Lymphomes Malins B”
regimen and their outcome and to identify prognostic factors for survival, we studied relapses in the LMB89, 96
and 2001 studies of the Société Française d’Oncologie Pédiatrique (Société Française des Cancers de l’Enfant). Therapeutic
guidelines at relapse were to obtain a second complete remission and to consolidate the remission with high-dose
chemotherapy followed by autologous stem-cell transplantation. Between July 1989 and March 2007, 67 patients
of 1322 (5%) relapsed: 57 had Burkitt lymphoma and 10 had large-cell histology. Three patients were initially treat-
ed in risk group A, 41 in group B and 23 in group C. Thirty-three patients had a relapse in one site (15 in the central
nervous system) and 34 at multiple sites. Sixty-five patients received salvage chemotherapy and 33 achieved com-
plete remission. Forty-one patients also received high-dose chemotherapy followed by autologous (n=33) or allo-
geneic (n=8) transplantation. With a median follow-up of 6.4 years, the 5-year survival rate was 29.9%. Nineteen
patients were still alive, all but one (group A) received consolidation treatment. Multivariate analysis showed the
following factors to be significantly associated with better survival: relapse at one site (P=0.0006), large-cell histol-
ogy (P=0.012), initial prognostic group A or B with lactate dehydrogenase level below twice the normal value
(P=0.005), and time to relapse more than 6 months (P=0.04).
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ABSTRACT
Initial treatment 
In each of the three studies, patients were assigned to one of
three treatment groups (A, B and C) based on the stage of initial
disease,2,3,5,6 and received two (group A), four or five (group B), or
eight (group C) courses of chemotherapy. Rituximab was not used
in initial treatment. Group A patients (completely resected stage I
and abdominal stage II) did not receive central nervous system
(CNS) prophylaxis (no intrathecal treatment, no HD methotrex-
ate). Patients in group C (stage IV with CNS involvement and B-
AL) received HD methotrexate at a dose of 8 g/m2, and consolida-
tion courses which consisted of HD cytarabine and etoposide
(CYVE). In group B (all patients not in group A or group C),
patients received HD methotrexate at a dose of 3 g/m2 and cytara-
bine in a 5-day continuous infusion during consolidation. Group B
patients were switched to group C if tumor regression was less
than 20% 7 days after the pre-phase COP (cyclophosphamide,
oncovin, and prednisone), or if complete remission was not
achieved after the first course of consolidation. There were only
minor differences among the three studies, allowing the results to
be combined and analyzed (see Online Supplementary Material).
Recommendations for treatment of relapse
Although there was no prospective trial for treatment of relapse
within the LMB protocols, there were general therapeutic recom-
mendations. The first one was to obtain a second complete remis-
sion with salvage chemotherapy, based on the previous therapy:
group C therapy/CYVE course for group A patients, and CYVE
courses for group B patients. Salvage chemotherapy was more het-
erogeneous for patients who had already received group C therapy
(initially or after switching from group B), depending on the time
period of the study and the type of relapse: most patients under-
went therapy with VENOMID (vindesine, novantrone, methyl-
prednisolone, ifosfamide), ICN (ifosfamide, carboplatin and
novantrone) or ICE (ifosfamide, carboplatin, etoposide, and triple
intrathecal therapy). Treatment recommended for CNS relapse
was two weekly courses of HD methotrexate (8 or 12 g/m2 as 24-
hour infusions), with intrathecal therapy, potentially followed by
another chemotherapy regimen. 
The second recommendation was to consolidate the second
complete remission with HD chemotherapy and autologous
HSCT. The HD chemotherapy was most often either BEAM
(BCNU, VP-16, aracytine and melphalan) or BAM (busulfan, aracy-
tine, and melphalan), depending on the histology, time period of
the study, and type of relapse. However, some investigators pre-
ferred total body irradiation-containing regimens with allogeneic
HSCT. The anti-CD20 monoclonal antibody (rituximab) was
added to the salvage chemotherapy for some patients after 1996.
Other details on patients, histopathology/immunophenotyp-
ing, responses, statistics and HD chemotherapy regimens are pre-
sented in the Online Supplementary Methods and Online
Supplementary Table SA.  
Results
Patients’ initial characteristics 
Sixty-seven of 1322 patients (5%) (27/562, 23/383 and
17/377 in LMB89, 96 and 2001, respectively) relapsed: 57
with BL, six with DLBCL and four with primary mediasti-
nal B-cell lymphoma (PMBL). Their characteristics at diag-
nosis are presented in Table 1. The majority had advanced
stage disease. Twenty-five patients had bone marrow and
12 had CNS involvement. Forty-seven (70%) patients had a
lactate dehydrogenase (LDH) level > twice the normal level
(2N): 0 in group A, 66% in group B and 87% in group C.
Three group B patients with stage III and LDH>2N were
switched to group C after COP (n=2) or the first consolida-
tion course (n=1).
Characteristics of relapses 
The median age at time of relapse was 9.6 years (range,
1-19.6 years). The median time to relapse after diagnosis
was 4.8 months (range, 2.3-14.1 months) in BL and 22.1
months (range, 4.2-32.2 months) in all patients with large-
cell histology (DLBCL and PMBL). Relapse occurred in one
site in 33 patients, while 34 patients had relapse in multiple
sites [including bone marrow (n=25) or CNS (n=10)].
Relapse occurred in both bone marrow and the CNS in
eight patients (Table 1).
Table 1. Patients’ initial characteristics and relapse modalities, overall and
according to histology.
All patients Burkitt DLBCL PMBL
(n=67) and NOS (n=6) (n=4)
(n=57)
Initial characteristics
Male 50 (75%) 46 3 1
Female 17 (25%) 11 3 3
<15 years 56 (84%) 52 3 1
≥15 years 11 (16%) 5 3 3
Stage I 2 (3%) 1 1 0
Stage II 4 (6%) 3 1 0
Stage III 33 (49%) 27 2 4
Stage IV (BM < 25%) 10 (15%) 10 0 0
BM positive 4 4
CNS positive 3 3
BM&CNS positive 3 3
B-AL or BM >25% 18 (27%) 16 2 0
CNS positive 6 6 0
LMB89 27 (40%) 23 3 1
LMB96 23 (34%) 20 1 2
LMB01 17 (25%) 14 2 1
Group A 3 (4%) 3 0 0
Group B 41 (61%) 33 4 4
LDH<2N 12 7 3 2
LDH>2N 27 24 1 2
LDH unknown 2 2 0 0
Group C 23 (34%) 21 2 0
Relapse characteristics 
Median time to relapse 5.0 4.8 26.9 8.9 
(months) (range) (2.3-32.2) (2.3-14.1) (4.2-32.2) (5.7-25.7)
Time to relapse ≤ 6 m 45 (67%) 43 1 1
Time to relapse 16 (24%) 14 0 2
between 6 m and 15 m
Time to relapse >15 m 6 (9%) 0 5 1
Relapse in single site 33 (49%) 27 4 2
Local relapse 12 8 2 2
CNS relapse 15 15 0 0
BM relapse 1 0 1 0
Other 5 4 1 0
Multiple site relapse      34 (51%) 30 2 2
Including local 19 16 1 2
CNS 10 9 1 0
BM 25 22 2 1
NOS: aggressive B-cell lymphoma not otherwise specified; BM: bone marrow; CNS: central nerv-
ous system; DLBCL: diffuse large B-cell lymphoma; LDH: lactate dehydrogenase; PMBL: primary
mediastinal B cell lymphoma.
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Salvage chemotherapy
Two FAB/LMB96 patients did not receive salvage
chemotherapy: one group B patient considered to need pal-
liative care and one group C patient considered to be in
complete remission after excision of the abdominal mass
seen at relapse. The other 65 patients received one or more
(maximum 3) lines of rescue chemotherapy, depending on
the initial treatment group (Table 2). Sixteen patients [11
group B and 5 group C; 12 BL (8 group B, 4 group C), 3
DLBCL, 1 PMBL] also received rituximab (4 in FAB/LMB96
and 12 in LMB2001).
Response to salvage chemotherapy 
One group A patient died of toxicity after the first CYVE
course. Thirty-two patients were considered to be in com-
plete remission after salvage chemotherapy, 26 after first-
line treatment and six after another line. Including the
patient treated by surgery only, 33 patients (49%) were con-
sidered to be in complete remission after salvage treatment.
Eight patients were in partial remission, two had stable dis-
ease and 22 had progressive disease.
First salvage response (complete + partial remission) rates
were 67% (2/3 patients) with the group C regimen/CYVE
after group A, 66% (19/29 patients) with CYVE after group
B and 60% (3/5 patients) with ICE after group C therapy. Of
the responding patients, 2/2, 11/19 and 3/3 patients are still
alive, respectively. The response rate in group B patients
after CYVE was 86% (6/7) in patients with low LDH levels
and 60% (12/20) in those with high LDH levels (P=0.36) and
complete remission rates were 71% (5/7) and 45% (9/20)
(P=0.38), respectively (LDH was missing for 2 patients). Six
of the 16 patients who received rituximab were in complete
remission after salvage treatment (Table 2).
Consolidation therapy
Forty-one patients (61%) without progressive disease
received HD chemotherapy as consolidation therapy.
Thirty-three patients received HD chemotherapy followed
by autologous HSCT, 27 of whom were in complete remis-
sion (1 group A, 15 group B and 11 group C), five in partial
remission and one had stable disease. Eight patients (4 with
bone marrow involvement at relapse) received HD
chemotherapy followed by allogeneic HSCT (6 genoidenti-
cal, one using umbilical cord cells and one peripheral stem
cells from the father), five were in complete remission, two
in partial remission, and one had stable disease (Table 2).
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Table 2. Characteristics of salvage chemotherapy and of consolidation with type of graft.
Initial risk group Total number CR Response
A B C of patients rate rate (CR+PR)
First salvage chemotherapy 3 39 23 65 (97%) 26/62* (42%) 34/62* (55%)
CYVE 1$ 31* 1 33 15/31* (48%) 19/31* (61%)
Methotrexate 1 9* 10 5/9* (56%) 5/9* (56%)
ICE 2 3 5 2/5 (40%) 3/5 (60%)
ICN 1 2 3 0/3 (0%) 1/3 (33%)
LMB group C 2 2 1/2 (50%) 1/2 (50%)
DHAP 1 1 0/1 (0%) 1/1 (100%)
Unknown 1 1 0/1 (0%) 0/1 (0%)
Other 3 7 10 2/10 (20%) 3/10 (30%)
Second salvage chemotherapy 27 (40%) 6/27 (22%) 11/27 (41%)
Methotrexate 1 1 1 3 1/3 1/3
ICE 3 1 4 0/4 1/4
COP(ADM) 4 1 5 2/5 3/5
Cyclophosphamide 2 3 5 1/5 1/5
DHAP 1 1 2 1/2 1/2
Other 5 3 8 1/8 4/8
Response to salvage chemotherapy
Complete remission 2 (67%) 19 (49%) 11 (48%) 32 (49%)
Partial remission 0 7 (18%) 1 (4%) 8 (12%)
Stable disease 0 1 (2%) 1 (4%) 2 (3%)
Progression 0 12 (31%) 10 (44%) 22 (34%)
Toxic death 1 (33%) 0 0 1 (2%)
Consolidation with HDC and HSCT 41/67 (61%)
Autograft 1 22 10 33
BEAM 0 17 6 23
BAM 1 2 3 6
Bu-Mel (+/- cyclophosphamide) 0 2 1 3
Other 0 1 0 1
Allograft 0 5 3 8
TAM 0 1 2 3
TBI-cyclophosphamide 0 4 0 4
Unknown 0 0 1 1
$Toxic death after one course of CYVE; * Three patients not evaluated after the first salvage chemotherapy: two group B patients treated with CYVE and one group C patient treated
with methotrexate.  CR: complete response; PR: partial response; HDC: high dose chemotherapy; HSCT: hematopoietic stem cell transplantation; TBI: total body irradiation.
Radiotherapy
Nine patients also received radiotherapy (7 LMB89 and 2
FAB/LMB96). Five out the 31 patients with relapse at the
primary site were admnistered local irradiation (3 PMBL,
one bone DLBCL, one abdominal BL). Four patients were
given cranial irradiation (with or without spinal irradiation)
for CNS relapse.
Overall survival
The median follow-up time was 6.4 years. All living
patients were followed for more than 3 years after relapse
(3.2 to 17 years). The 5-year survival rate was 29.9% [95%
confidence interval (95% CI): 20.2-41.7%] (Figure 1). 
Forty-eight patients died, with all but one of the deaths
occurring within 12 months after relapse. Forty-three of the
patients died of disease (24 before and 19 after HSCT),
while five died of treatment-related toxicity [1 during sal-
vage chemotherapy, 3 after HD chemotherapy (1 BEAM +
autologous HSCT, 2 total body irradiation + allogeneic
Survival of children with B-NHL/B-AL after relapse
haematologica | 2015; 100(6) 813
Figure 1. Probability of survival after relapse (vertical bars denote the
Rothman 95% confidence interval).
Table 3. Univariate and multivariate prognostic analyses of survival after relapse.
Univariate analysis Multivariate analysis Multivariate analysis
All patients All patients Burkitt lymphoma
(n=67) (n=65*) (n=55*)
N. 5-year rate P HR 95% CI P HR 95% CI P
LMB89 27 25.9%
LMB96 23 30.4%
LMB01 17 35.3% 0.60
Male 50 24.0%
Female 17 47.1% 0.12
<15 years 56 26.8%
≥15 years 11 45.5% 0.054
Stage I 2 100%
Stage II 4 50.0%
Stage III 33 30.3%
Stage IV 10 20.0%
ALL 18 22.2% 0.24
Group A 3 66.7% 1** 1**
Group B LDH<2N* 12 75.0%
Group B LDH>2N* 27 14.8% 4.6 [1.5-13.8] 4.1 [1.3-12.4]
Group C 23 17.4% 0.005 6.6 [2.1-20.6] 0.005 6.3 [2.0-19.9] 0.007
No DLBCL 57 22.8% 1
DLBCL 10 70.0% 0.003 0.21 [0.06-0.70] 0.012
Time to relapse ≤ 6 months 45 22.2% 1 1
Time to relapse >6 months 22 45.5% 0.02 0.45 [0.21-0.96] 0.04 0.39 [0.18-0.88] 0.02
Relapse in one site 33 42.4% 1 1
Multiple site relapse 34 17.7% 0.004 3.1 [1.6-6.1] 0.0006 3.3 [1.7-6.5] 0.0005
No CNS relapse 42 33.3%
CNS relapse 25 24.0% 0.33
No BM relapse 41 39.0%
BM relapse 26 15.4% 0.009
Salvage chemotherapy
CYVE 35 40.0%
Methotrexate 10 10.0%
ICE 5 60.0%
Other 15 13.3% 0.007
No rituximab 51 25.5%
Rituximab 16 43.8% 0.29
* LDH missing for two patients in group B; ** Reference category is patients of group A and group B LDH<2N; DLBCL: diffuse large B-cell lymphoma including primary mediastinal
lymphoma; BL: Burkitt lymphoma. 
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HSCT) and 1 of respiratory failure 5 years after total body
irradiation + allogeneic HSCT and several CNS relapses]. 
Nineteen patients were still alive: one group A patient
rescued with the group C regimen without consolidation
and 18 after consolidation therapy (1 group A, 14 group B
and 3 group C) (Online Supplementary Figure S1). The 5-year
survival rates in groups A, B and C were 66.7%, 34.2%, and
17.4%, respectively.
Among patients irradiated after HD chemotherapy, four
are still alive after local radiation (1 DLBCL, 2 PMBL, 1 BL)
and one with BL after cranio-spinal irradiation for CNS
relapse.
Prognostic analysis of overall survival 
The following factors were significantly associated with
survival in the univariate analysis: initial risk group com-
bined with LDH level in group B (group A and group B with
LDH ≤2N versus group B with LDH>2N and group C), his-
tology [large-cell (DLBCL and PMBL) versus others], time to
relapse (more than 6 months versus within 6 months after
diagnosis), number of sites at relapse (relapse in one site ver-
sus multiple sites) and type of rescue therapy (CYVE and
ICE versus others) (Figure 2 and Table 3).
In the multivariate analysis, risk group A or B with LDH
≤2N (P=0.005), large-cell histology (P=0.012), relapse after 6
months (P=0.04) and relapse at one site (P=0.0006) were
still independently associated with better survival (Table 3).
Among the patients who relapsed in the CNS, 4/15 with
an isolated relapse (1 group A, 2 group B and 1 group C) and
1/10 with combined relapse (group B) are alive. Their sal-
vage included HD methotrexate with or without HD
cytarabine. The four surviving patients with isolated relapse
received either BEAM (n=2) or BAM (n=2) consolidation
followed by autologous HSCT. One other patient with an
isolated CNS relapse died from a late complication 5 years
following allogeneic HSCT. The only surviving patient with
a combined relapse (bone marrow + CNS) had a DLBCL
and received total body irradiation-cyclophosphamide with
an allograft (Online Supplementary Table SB). 
Rituximab administration was not significantly associat-
ed with survival (P=0.29 in univariate analysis and P=0.10
after adjustment for the other risk factors identified).
Survival was similar among patients with BL not given
(n=45) or given (n=12) rituximab (5-year survival rates
22.2% and 25.0%, respectively, P=0.82, P=0.22 after adjust-
ment). Four of the ten patients who had large-cell histology
received rituximab. Their 5-year survival rate was 100%,
while the survival rate of the six patients who did not
receive rituximab was 50% (P=0.11). 
The ten patients with large cell histology had better sur-
vival than the other patients. The small sample size prohib-
ited a prognostic analysis, but it is worth noting that this
subgroup more often had a low LDH level, relapse at one
site, and late relapse (Online Supplementary Table SC). More
A. Jourdain et al.
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Figure 2. Probability of survival after relapse according to the four independent prognostic factors (vertical bars denote the Rothman 95% con-
fidence interval).
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importantly, the multivariate prognostic analysis that
included the 55 patients who did not have large-cell histol-
ogy showed the same prognostic factors as those of the
whole cohort.
Factors associated with survival after consolidation with
hematopoietic stem cell transplantation
The survival rate of the 41 patients who received consol-
idation HD chemotherpay with HSCT was 46.3% (95%
CI: 32-61%). Eighteen patients were still alive [16/33 after
autologous HSCT (BEAM 12/23; busulfan-based 3/9; other
1/1) and 2/8 after allogeneic HSCT]. The type of graft and
the response status at the time of HSCT were not signifi-
cantly associated with survival (Figure 3); however, the
power of the analyses was low due to the small sample
size. The three patients in partial remission who were still
alive after autologous HSCT were in fact in very good par-
tial remission without histological study of the residual
mass (2 PMBL and 1 cervical BL). They could have been
considered as having “unconfirmed” complete remission.
The survival of the 35 patients who received transplants in
definitive or unconfirmed complete remission was signifi-
cantly better than that of the six other patients (54.3% ver-
sus 0%, P=0.016).
Discussion
Relapse of childhood B-NHL following the SFOP/SFCE
LMB89, 96 and 2001 protocols has been rare (5% of
patients). The overall survival rate was 29.9%, despite sal-
vage chemotherapy in 97% of patients, and HD
chemotherapy with HSCT in 61%. This study showed that
relapse of BL occurred earlier (median time to relapse 5
months after diagnosis) compared to that of DLBCL (27
months). It also showed that Burkitt histology and initial
therapeutic group C and B with LDH >2N were poor prog-
nostic factors, as were early relapse (<6 months) and relapse
at multiple sites. 
Few studies have specifically focused on relapse in child-
hood B-NHL4,7,9–11,15–17,20–23 Survival was generally less than
30%. It is generally accepted that a good response to sal-
vage treatment before HD chemotherapy is essential and
that patients with progressive disease should not receive
HD chemotherapy.4,10 In our study, the number of patients
treated with each type of rescue chemotherapy was too
small to be able to compare the response rates between res-
cue types with adequate power. However, the CYVE regi-
men24 seemed to be effective rescue for patients initially
treated with the group A regimen and group B patients with
LDH ≤2N. Rescue chemotherapy and the second complete
remission rate should be improved for other patients, while
the R-ICE regimen may be a promising rescue chemothera-
py.25–27 The benefit of rituximab in combination with HSCT
has been shown in adults with relapsed DLBCL.26,28 Some
case reports and a recent UK series have suggested benefi-
cial effects of rituximab in relapsed children.11,18,19,29
However, only 16 patients received rituximab in our study,
thus, the power was inadequate to evaluate the effects of
rituximab. The role of local radiotherapy was also not
assessable, but may be of interest in some cases of local
relapse of DLBCL. 
Philip et al. reported that relapsed patients have subse-
quent relapses if intensification of treatment is not adminis-
tered.4 The survival of HSCT recipients varies, depending
mainly on the status at the time of the transplant, with bet-
ter outcome for patients in second complete remission.4,7–9,12–
14 We could not demonstrate that being in second complete
remission at the time of HDC was significantly associated
with survival, but overall, patients in second or uncon-
firmed complete remission had better survival than others.
The type of HSCT had no impact on outcome. Allogeneic
HSCT was not more beneficial than autologous HSCT (sur-
vival rate of 38% versus 49%, respectively) and caused more
toxicity. A graft-versus-lymphoma effect has not been
shown in BL.9,15,30–32 In particular, the review published by
Gross et al. showed similar event-free survival rates in BL
(n=41) and DLBCL (n=52) with autologous HSCT and allo-
geneic HSCT (27% versus 31% and 52% versus 50%,
respectively), which is in contrast to the clear advantage of
allogeneic HSCT in lymphoblastic lymphoma.15 BEAM and
busulfan-based regimens were both administered before
autologous HSCT, but a conclusion could not be drawn
regarding the benefits of each regimen, which were not ran-
Survival of children with B-NHL/B-AL after relapse
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Figure 3. Probability of survival after relapse among the 41 patients treated with hematopoietic stem cell transplantation according to (A) the
type of graft and (B) the response status at the time of high-dose chemotherapy (vertical bars denote the Rothman 95% confidence interval)
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domized and administered at the investigators’ discretion.
Nevertheless, the consolidation regimen for high-risk
patients needs to be improved.
Previous studies on BL found that one-third of relapses
occurred in the CNS, one-third at the primary site and one-
third at other sites.14 We observed a comparable distribution
in our study (22% isolated CNS, 27% unifocal and 51%
multifocal). Survival differed according to the site of relapse,
in contrast with previously published results.4 Relapse at
one site was significantly associated with better survival
(42% versus 18% at multiple sites). CNS relapse has been
shown to be curable.4,9,33 In our study, four out of 15 patients
with isolated CNS relapse were still alive.
Although no differences in survival in DLBCL and BL were
observed in the LMB studies or in the BFM studies,2,3,34,35 large-
cell histology was associated with better survival after relapse
(70% versus 23%) and lower risk characteristics, which is
consistent with the fact that they are different entities.35,36
Advanced disease and LDH level are recognized as poor
prognostic factors at diagnosis; interestingly, they were sig-
nificant prognostic factors at relapse.11,37 Thus, group A and
group B patients with low LDH levels had better survival
(67% and 75%, respectively) than group B patients with
high LDH levels and group C patients (15% and 17%,
respectively). It should be noted that initial risk stratification
was not only indicative of initial tumor burden, but also of
treatment burden before relapse. This emphasizes the need
for an effective first-line treatment and the necessity to be
very cautious with any reduction of this first-line therapy
because of the lack of a solid second chance in these groups
of patients. 
In conclusion, our series is one of the largest cohorts of
relapsed pediatric patients to date. We confirmed that early
relapse (<6 months) was a significant factor contributing to
inferior outcome, and that the source of stem cells (autolo-
gous versus allogeneic) did not affect outcome. Moreover, we
observed that initial low-risk disease at diagnosis, large-cell
histology, and localized relapse are associated with better
outcome. For the patients with unfavorable characteristics,
(i.e., those initially in group B with high LDH levels, those in
group C, and those with early and multi-site relapse), new
treatment combinations are necessary to improve the second
complete remission rate before HD chemotherapy and
HSCT. New drugs, including antibodies and targeted thera-
py, should be investigated, as should be a double HSCT res-
cue strategy. In CNS relapses the place of intrathecal/intra-
ventricular antibodies also needs to be investigated. Due to
the small number of relapsing patients, these investigations
should be conducted on an international level.
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